The VISTA T cell-inhibiting protein found on macrophage immune cells may contribute to poor pancreatic ductal adenocarcinoma outcomes, new research finds.
In a small study, melanoma patients with BRAF V600K mutations responded better to immunotherapy while those with V600E mutations had a better response to targeted therapy.
In a colon cancer model, researchers saw transcriptional changes and population expansions in some checkpoint receptor-negative tumor-infiltrating T cells.
The company has pivoted to serve the research market but still hopes to spearhead translation of immunotherapy biomarkers following CLIA validation of its approach.
The study authors cautioned that immunological signatures cannot be predicted from tumor mutational burden or microenvironment analysis of a single biopsy alone.
The company is currently using the model, named EDGE, in its own personalized cancer vaccine work and in collaboration with outside immunotherapy developers.
The researchers will not only explore tissue and circulating biomarkers but also the role of the microbiome in predicting benefit from immune checkpoint inhibitors.
H3, a subsidiary of Japanese drugmaker Eisai, is developing personalized cancer treatments targeting genomic alterations, including aberrant RNA splicing.
